Drug Profile

Research programme: antimicrobial immunoconjugate cancer therapeutics - Merck & Co

Latest Information Update: 28 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cidara Therapeutics
Developer Merck & Co
Class Antibacterials; Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fc fragments
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Feb 2026 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
07 Jan 2026 Cidara Therapeutics has been acquired and merged into Merck & Co
31 Jan 2022 Research programme: antimicrobial immunoconjugate cancer therapeutics - Cidara Therapeutics is available for licensing as of 31 Jan 2022. https://www.cidara.com/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com